The road ahead for HIV/AIDS funding: Keeping the eye on the prize
This article was originally published in Scrip
With the US Congress currently wrestling with whether the richest of Americans should continue to get tax breaks and how to keep the nation from falling off the fiscal cliff come January, putting the renewal for vital programs for HIV/AIDS prevention and treatments as a priority atop the agendas for the House and Senate, despite past bipartisan support, may take some wrangling.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.